Evolus, Inc. (EOLS) |
|
11.69 0.09 (0.78%)
|
07-02 20:32 |
|
Open: |
11.6 |
Pre. Close: |
11.6 |
|
High:
|
11.85 |
Low:
|
11.5 |
|
Volume:
|
227,900 |
Market Cap:
|
655(M) |
|
|
|
|
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.86 - 11.91 |
11.91 - 11.96 |
|
Low:
|
11.38 - 11.43 |
11.43 - 11.48 |
|
Close:
|
11.6 - 11.68 |
11.68 - 11.77 |
|
Technical analysis |
as of: 2022-07-01 4:21:38 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
| Target: |
Six months: 14.92 One year: 16.7 |
| Support: |
Support1: 10.31 Support2: 8.57 |
| Resistance: |
Resistance1: 12.77 Resistance2: 14.3 |
| Pivot: |
11.78 |
| Moving Average: |
MA(5): 11.91  MA(20): 11.93
MA(100): 11.18 MA(250): 9.3 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 45.3 %D(3): 51.4 |
| RSI: |
RSI(14): 46.4 |
| 52-week: |
High: 14.34 Low: 5.06 |
| Average Vol(K): |
3-Month: 522 (K) 10-Days: 461 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ EOLS ] has closed above bottom band by 44.3%. Bollinger Bands are 24.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Tue, 28 Jun 2022
Evolus, Inc. (NASDAQ:EOLS) Receives $15.33 Consensus Target Price from Brokerages - Defense World
Wed, 15 Jun 2022
County libraries offer summer opportunities - Sequoyah County Times
Tue, 14 Jun 2022
Shareholders in Evolus (NASDAQ:EOLS) have lost 19%, as stock drops 11% this past week - Simply Wall St
Sun, 12 Jun 2022
Our view: A first-class show in Union - La Grande Observer
Mon, 23 May 2022
Evolus Inc (EOLS) has fallen -15.38% in a Week, Should You Accumulate? - InvestorsObserver
Wed, 11 May 2022
Evolus stock rises as Q1 revenue soars 177% Y/Y - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
56 (M) |
| Shares Float |
37 (M) |
|
% Held by Insiders
|
33.4 (%) |
|
% Held by Institutions
|
46.3 (%) |
|
Shares Short
|
3,040 (K) |
|
Shares Short P.Month
|
2,280 (K) |
Stock Financials |
|
EPS
|
-1.3 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.2 |
|
Profit Margin (%)
|
-58.3 |
|
Operating Margin (%)
|
-50.8 |
|
Return on Assets (ttm)
|
-20.4 |
|
Return on Equity (ttm)
|
-156.3 |
|
Qtrly Rev. Growth
|
177 |
|
Gross Profit (p.s.)
|
1 |
|
Sales Per Share
|
2.16 |
|
EBITDA (p.s.)
|
-1.02 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-63 (M) |
|
Levered Free Cash Flow
|
-33 (M) |
Stock Valuations |
|
PE Ratio
|
-9 |
|
PEG Ratio
|
-0.8 |
|
Price to Book value
|
9.74 |
|
Price to Sales
|
5.39 |
|
Price to Cash Flow
|
-10.36 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
